IRIS
BARGAGLI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.778
EU - Europa 24.640
AS - Asia 13.783
SA - Sud America 2.483
AF - Africa 751
OC - Oceania 56
Continente sconosciuto - Info sul continente non disponibili 16
AN - Antartide 1
Totale 68.508
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.201
IT - Italia 5.670
RU - Federazione Russa 5.240
SG - Singapore 4.311
CN - Cina 3.736
GB - Regno Unito 3.724
IE - Irlanda 2.996
BR - Brasile 2.040
VN - Vietnam 1.788
SE - Svezia 1.382
FR - Francia 1.368
DE - Germania 1.364
HK - Hong Kong 1.295
FI - Finlandia 825
UA - Ucraina 807
KR - Corea 565
IN - India 528
ZA - Sudafrica 360
BD - Bangladesh 358
CA - Canada 334
ES - Italia 267
NL - Olanda 256
JP - Giappone 186
IQ - Iraq 165
PL - Polonia 150
MX - Messico 146
TR - Turchia 146
AR - Argentina 137
CZ - Repubblica Ceca 112
AT - Austria 100
CI - Costa d'Avorio 94
NG - Nigeria 89
PK - Pakistan 82
EC - Ecuador 71
ID - Indonesia 69
UZ - Uzbekistan 64
BE - Belgio 62
SA - Arabia Saudita 58
IR - Iran 54
VE - Venezuela 54
MA - Marocco 50
CO - Colombia 46
KE - Kenya 46
PH - Filippine 46
AU - Australia 45
CL - Cile 40
CH - Svizzera 39
AE - Emirati Arabi Uniti 38
LT - Lituania 35
JO - Giordania 34
EG - Egitto 32
PY - Paraguay 31
PT - Portogallo 30
AZ - Azerbaigian 29
PE - Perù 28
MY - Malesia 26
IL - Israele 25
RO - Romania 25
KZ - Kazakistan 23
DK - Danimarca 22
GR - Grecia 21
DZ - Algeria 20
JM - Giamaica 20
BG - Bulgaria 18
TN - Tunisia 18
AL - Albania 15
BO - Bolivia 15
ET - Etiopia 14
KG - Kirghizistan 14
LB - Libano 14
LV - Lettonia 14
NP - Nepal 14
UY - Uruguay 14
HU - Ungheria 13
OM - Oman 13
EE - Estonia 12
PA - Panama 12
SN - Senegal 11
CR - Costa Rica 10
CY - Cipro 10
PS - Palestinian Territory 10
TT - Trinidad e Tobago 10
BY - Bielorussia 9
EU - Europa 9
GE - Georgia 9
HN - Honduras 9
LK - Sri Lanka 9
MK - Macedonia 9
NO - Norvegia 9
DO - Repubblica Dominicana 8
QA - Qatar 8
RS - Serbia 8
TW - Taiwan 8
LA - Repubblica Popolare Democratica del Laos 7
NZ - Nuova Zelanda 7
TH - Thailandia 7
AM - Armenia 6
BB - Barbados 6
GY - Guiana 6
HR - Croazia 6
Totale 68.396
Salva come PNG Salva come JPEG
Città #
Dallas 4.525
Southend 3.025
Dublin 2.956
Singapore 2.556
Fairfield 2.071
Ashburn 2.032
Moscow 1.534
San Jose 1.509
Chandler 1.426
Santa Clara 1.380
Hong Kong 1.205
Beijing 923
Woodbridge 880
Siena 817
Hefei 788
Houston 782
Seattle 762
Wilmington 698
Cambridge 630
Jacksonville 588
Los Angeles 587
Council Bluffs 584
Milan 565
Seoul 529
Ho Chi Minh City 514
Helsinki 506
Munich 486
New York 474
Princeton 473
Hanoi 409
Ann Arbor 405
Florence 389
Lauterbourg 377
Lastra a Signa 349
The Dalles 340
Johannesburg 322
Rome 246
São Paulo 190
Dong Ket 184
Nanjing 178
Buffalo 177
Chicago 164
Boardman 162
Shanghai 161
San Diego 159
Orem 152
London 146
Tokyo 141
Dearborn 138
Bengaluru 137
San Mateo 127
Turku 123
Frankfurt am Main 120
Málaga 120
Warsaw 120
Redondo Beach 117
Fremont 102
Nuremberg 99
Da Nang 96
Lappeenranta 96
Abidjan 93
Chennai 90
Montreal 84
Düsseldorf 82
Abuja 77
Brooklyn 76
Nanchang 74
Toronto 74
Haiphong 73
Stockholm 70
Atlanta 67
Phoenix 67
Portsmouth 67
Brno 66
Denver 66
Rio de Janeiro 64
Washington 61
Baghdad 57
Manchester 57
Vienna 57
Guangzhou 56
Menlo Park 55
Amsterdam 54
Tashkent 54
Poplar 53
Naples 52
San Francisco 52
Shenyang 52
Ottawa 51
Columbus 50
Mexico City 47
Boston 46
Catania 46
Changsha 46
Bologna 45
Brussels 43
Paris 43
Hangzhou 42
Gavirate 41
Belo Horizonte 40
Totale 44.241
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.043
A first update on mapping the human genetic architecture of COVID-19 582
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 577
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 504
Genetic mechanisms of critical illness in COVID-19 430
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 418
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 389
Cytokine modulators in the treatment of sarcoidosis 386
An explainable model of host genetic interactions linked to COVID-19 severity 371
Antirheumatic agents in covid-19: is IL-6 the right target? 360
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 356
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 356
Pathogen-sugar interactions revealed by universal saturation transfer analysis 355
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 351
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 344
null 320
Peripheral biomarkers' panel for severe COVID-19 patients 319
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 314
Colonizzazione e trapianto di polmone: il possibile ruolo dei colonizzanti multiresistenti sugli eventi infettivi in uno studio pilota osservazionale-retrospettivo 312
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 306
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 303
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 298
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 298
POS0871 diagnostic accuracy og power doppler ultrasonography for the diagnosis of idiopathic inflammmatory myopathies 294
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 294
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 291
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 290
Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity 288
Accuracy of power Doppler ultrasonography in the diagnosis and monitoring of idiopathic inflammatory myopathies 287
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 285
Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways 284
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 282
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 281
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 275
Exhaled nitric oxide in interstitial lung diseases 274
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 274
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 273
Gorham-Stout disease management during pregnancy 266
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 266
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 264
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 264
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1 262
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? 262
Increased Risk of Atherosclerosis in Patients with Sarcoidosis 261
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 261
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 258
Prognostic bioindicators in severe COVID-19 patients 256
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 256
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 255
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 251
Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis 250
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 250
Serial KL-6 measurements in COVID-19 patients 249
Omalizumab treatment in Samter's triad: case series and review of the literature 247
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 247
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 246
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 246
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 242
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 242
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 241
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 241
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 240
Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases 239
Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 238
Serum amyloid A in patients with idiopathic pulmonary fibrosis 237
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 237
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 237
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 237
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 237
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 236
A functional proteomics approach to the comprehension of sarcoidosis 235
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 233
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 232
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 232
Chitotriosidase activity in patients with interstitial lung disesaes 231
NK and NKT-like cells in granulomatous and fibrotic lung diseases 228
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 228
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 227
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 227
Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer 226
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline 226
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 225
Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent 225
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. 225
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 225
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 223
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 223
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 222
Strategies for Maximising Lung Utilisation in Donors After Brain and Cardiac Death: A Narrative Review 221
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 219
SARS-CoV-2 in pleural fluid in a kidney transplant patient 219
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 218
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 217
Analysis of carbonylated proteins in BAL of patients with diffuse lung diseases 217
Pirfenidone in chronic lung allograft dysfunction: a single cohort study 217
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 217
Chromosome 5 inversion in two siblings, one with Klinefelter syndrome and systemic sclerosis, the other with rheumatoid arthritis 216
Fibrotic Lung Toxicity Induced by Hydroxycarbamide 215
Cor pulmonale: the role of traditional and advanced echocardiography in the acute and chronic settings 215
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 215
Totale 28.184
Salva come PNG Salva come JPEG
Categoria #
all - tutte 228.809
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 228.809
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021530 0 0 0 0 0 0 0 0 0 0 0 530
2021/20224.498 350 593 368 305 222 157 199 211 185 526 484 898
2022/20235.729 424 592 717 691 415 1.044 359 485 447 202 213 140
2023/20245.524 218 138 517 273 294 1.280 1.644 226 62 179 179 514
2024/202512.165 715 524 1.290 671 1.397 660 611 736 943 617 1.273 2.728
2025/202628.405 2.060 3.922 3.596 3.385 5.267 1.078 3.571 886 1.093 1.968 977 602
Totale 69.998